Literature DB >> 11014690

Strategy for maximizing the use of arteriovenous fistulae.

G A Beathard1.   

Abstract

Increasing the use of arteriovenous fistulae in dialysis patients requires a specific strategy. In order to properly select patients for an arteriovenous fistula (AVF), it is essential that the nephrologist become knowledgeable about the subject and that an organized approach be followed. Both the arterial and venous systems must be evaluated. Evaluation of medical history, general physical examination, specific physical examination related to the vasculature of the extremity, vein mapping and duplex ultrasound studies are all important. It is very important to assess the size of the vessels involved. Although a newly created AVF should be allowed to fully mature prior to use, failure to develop should be evaluated early. Many cases of early failure can be successfully salvaged. Even if the patient has an arteriovenous graft, they should be evaluated at the time of every graft failure for the possibilities of creating a secondary AVF.

Entities:  

Mesh:

Year:  2000        PMID: 11014690     DOI: 10.1046/j.1525-139x.2000.00079.x

Source DB:  PubMed          Journal:  Semin Dial        ISSN: 0894-0959            Impact factor:   3.455


  4 in total

1.  Decreased cumulative access survival in arteriovenous fistulas requiring interventions to promote maturation.

Authors:  Timmy Lee; Ahsan Ullah; Michael Allon; Paul Succop; Mahmoud El-Khatib; Rino Munda; Prabir Roy-Chaudhury
Journal:  Clin J Am Soc Nephrol       Date:  2010-11-18       Impact factor: 8.237

Review 2.  Vascular access in haemodialysis: strengthening the Achilles' heel.

Authors:  Miguel C Riella; Prabir Roy-Chaudhury
Journal:  Nat Rev Nephrol       Date:  2013-04-16       Impact factor: 28.314

Review 3.  Vascular access today.

Authors:  Konstantinos Pantelias; Eirini Grapsa
Journal:  World J Nephrol       Date:  2012-06-06

4.  Thrombophilic risk factors and ABO blood group profile for arteriovenous access failure in end stage kidney disease patients: a single-center experience.

Authors:  Sunnesh Reddy Anapalli; Harini Devi N; Pvgk Sarma; Lokanathan Srikanth; Siva Kumar V
Journal:  Ren Fail       Date:  2022-12       Impact factor: 2.606

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.